Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Pelecopan · BCX9930

Small molecule · Inhibitor of Complement factor D (CFD) · developed by BioCryst Pharmaceuticals

Phase 2 Most advanced trial (none active)

BCRX Developer

2 Registered trials

What is Pelecopan?

Pelecopan is an orally bioavailable small molecule that binds and blocks complement factor D, a serine protease that cleaves complement factor B in the alternative complement pathway. It is studied in paroxysmal nocturnal hemoglobinuria (PNH).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: BCX9930
Drug type: Small molecule
Targets: Complement factor D (CFD)
Mechanism: Inhibitor of Complement factor D (CFD)
Pathways: alternative complement pathway, complement factor B cleavage
Therapy area: Hematology
Developer: BioCryst Pharmaceuticals (BCRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: JD988C0G6J

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05741346	Phase 2	Paroxysmal Nocturnal Hemoglobinuria	Terminated	BCRX
NCT05116787	Phase 2	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Terminated	BCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria (PNH)

More from BioCryst Pharmaceuticals

Berotralstat FDA approved Peramivir FDA approved Avoralstat Phase 3 BCX10013 Phase 1 BCX17725 Phase 1 Forodesine Phase 1/2 Galidesivir Phase 1 Ulodesine Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the BCRX page.

Follow BCRX, the company behind Pelecopan

See BCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BCRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z